These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 29922291)

  • 1. Transcriptomics of the Vaccine Immune Response: Priming With Adjuvant Modulates Recall Innate Responses After Boosting.
    Santoro F; Pettini E; Kazmin D; Ciabattini A; Fiorino F; Gilfillan GD; Evenroed IM; Andersen P; Pozzi G; Medaglini D
    Front Immunol; 2018; 9():1248. PubMed ID: 29922291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrapulmonary (i.pulmon.) Pull Immunization With the Tuberculosis Subunit Vaccine Candidate H56/CAF01 After Intramuscular (i.m.) Priming Elicits a Distinct Innate Myeloid Response and Activation of Antigen-Presenting Cells Than i.m. or i.pulmon. Prime Immunization Alone.
    Thakur A; Pinto FE; Hansen HS; Andersen P; Christensen D; Janfelt C; Foged C
    Front Immunol; 2020; 11():803. PubMed ID: 32457748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System.
    Ciabattini A; Pettini E; Fiorino F; Lucchesi S; Pastore G; Brunetti J; Santoro F; Andersen P; Bracci L; Pozzi G; Medaglini D
    Front Immunol; 2018; 9():380. PubMed ID: 29593710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder.
    Thakur A; Ingvarsson PT; Schmidt ST; Rose F; Andersen P; Christensen D; Foged C
    Vaccine; 2018 May; 36(23):3331-3339. PubMed ID: 29699790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide-specific T helper cells identified by MHC class II tetramers differentiate into several subtypes upon immunization with CAF01 adjuvanted H56 tuberculosis vaccine formulation.
    Prota G; Christensen D; Andersen P; Medaglini D; Ciabattini A
    Vaccine; 2015 Nov; 33(48):6823-30. PubMed ID: 26494626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the Antigen-Specific CD4(+) T Cell Response Induced by Prime-Boost Strategies with CAF01 and CpG Adjuvants Administered by the Intranasal and Subcutaneous Routes.
    Ciabattini A; Prota G; Christensen D; Andersen P; Pozzi G; Medaglini D
    Front Immunol; 2015; 6():430. PubMed ID: 26379666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-Isotope SPECT/CT Imaging of the Tuberculosis Subunit Vaccine H56/CAF01: Induction of Strong Systemic and Mucosal IgA and T-Cell Responses in Mice Upon Subcutaneous Prime and Intrapulmonary Boost Immunization.
    Thakur A; Rodríguez-Rodríguez C; Saatchi K; Rose F; Esposito T; Nosrati Z; Andersen P; Christensen D; Häfeli UO; Foged C
    Front Immunol; 2018; 9():2825. PubMed ID: 30555488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll like-receptor agonist Pam
    Kennerknecht K; Noschka R; Löffler F; Wehrstedt S; Pedersen GK; Mayer D; Grieshober M; Christensen D; Stenger S
    Med Microbiol Immunol; 2020 Apr; 209(2):163-176. PubMed ID: 32020284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary Administration of the Liposome-Based Adjuvant CAF01: Effect of Surface Charge on Mucosal Adjuvant Function.
    Müllertz OAO; Andersen P; Christensen D; Foged C; Thakur A
    Mol Pharm; 2023 Feb; 20(2):953-970. PubMed ID: 36583936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of Primary Immune Response by Different Vaccine Adjuvants.
    Ciabattini A; Pettini E; Fiorino F; Pastore G; Andersen P; Pozzi G; Medaglini D
    Front Immunol; 2016; 7():427. PubMed ID: 27781036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parenteral Vaccination With a Tuberculosis Subunit Vaccine in Presence of Retinoic Acid Provides Early but Transient Protection to
    Riccomi A; Piccaro G; Christensen D; Palma C; Andersen P; Vendetti S
    Front Immunol; 2019; 10():934. PubMed ID: 31130946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimize Prime/Boost Vaccine Strategies: Trained Immunity as a New Player in the Game.
    Palgen JL; Feraoun Y; Dzangué-Tchoupou G; Joly C; Martinon F; Le Grand R; Beignon AS
    Front Immunol; 2021; 12():612747. PubMed ID: 33763063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic Evaluation of Kinetics and Distribution of Muscle and Lymph Node Activation Measured by
    Win Z; Weiner Rd J; Listanco A; Patel N; Sharma R; Greenwood A; Maertzdorf J; Mollenkopf HJ; Pizzoferro K; Cole T; Bodinham CL; Kaufmann SHE; Denoel P; Del Giudice G; Lewis DJM
    Front Immunol; 2020; 11():613496. PubMed ID: 33613536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Routing dependent immune responses after experimental R848-adjuvated vaccination.
    van Aalst S; Jansen MAA; Ludwig IS; van der Zee R; van Eden W; Broere F
    Vaccine; 2018 Mar; 36(11):1405-1413. PubMed ID: 29409680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal boosting of H56:CAF01 immunization promotes lung-localized T cells and an accelerated pulmonary response to Mycobacterium tuberculosis infection without enhancing vaccine protection.
    Woodworth JS; Christensen D; Cassidy JP; Agger EM; Mortensen R; Andersen P
    Mucosal Immunol; 2019 May; 12(3):816-826. PubMed ID: 30760832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human.
    van Dissel JT; Joosten SA; Hoff ST; Soonawala D; Prins C; Hokey DA; O'Dee DM; Graves A; Thierry-Carstensen B; Andreasen LV; Ruhwald M; de Visser AW; Agger EM; Ottenhoff TH; Kromann I; Andersen P
    Vaccine; 2014 Dec; 32(52):7098-107. PubMed ID: 25454872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.
    Fomsgaard A; Karlsson I; Gram G; Schou C; Tang S; Bang P; Kromann I; Andersen P; Andreasen LV
    Vaccine; 2011 Sep; 29(40):7067-74. PubMed ID: 21767590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity.
    Kowalczyk A; Doener F; Zanzinger K; Noth J; Baumhof P; Fotin-Mleczek M; Heidenreich R
    Vaccine; 2016 Jul; 34(33):3882-93. PubMed ID: 27269061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.
    Leroux-Roels I; Forgus S; De Boever F; Clement F; Demoitié MA; Mettens P; Moris P; Ledent E; Leroux-Roels G; Ofori-Anyinam O;
    Vaccine; 2013 Apr; 31(17):2196-206. PubMed ID: 22643213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.